These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33998168)

  • 41. Foveal and Extrafoveal Effects of Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Cohort Study.
    Pinto C; Sousa K; Oliveira E; Mendonça L; Gentil R; Queirós L; Falcão M
    Semin Ophthalmol; 2022 Feb; 37(2):153-157. PubMed ID: 34027797
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optical coherent tomographic angiographic pattern of the deep choroidal layer and choriocapillaris after photodynamic therapy for central serous chorioretinopathy.
    Chan SY; Pan CT; Wang Q; Shi XH; Jonas JB; Wei WB
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1365-1372. PubMed ID: 31037490
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative efficacy of treatments for chronic central serous chorioretinopathy: A systematic review with network meta-analyses.
    van Dijk EHC; Feenstra HMA; Bjerager J; Grauslund J; Boon CJF; Subhi Y
    Acta Ophthalmol; 2023 Mar; 101(2):140-159. PubMed ID: 36178171
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy.
    Rabiolo A; Zucchiatti I; Marchese A; Baldin G; Sacconi R; Montorio D; Cicinelli MV; Querques L; Bandello F; Querques G;
    Eye (Lond); 2018 Jan; 32(1):55-66. PubMed ID: 29265111
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
    Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy.
    Kim YK; Ryoo NK; Woo SJ; Park KH
    Am J Ophthalmol; 2015 Jul; 160(1):72-84.e1. PubMed ID: 25887629
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
    Nicolò M; Zoli D; Musolino M; Traverso CE
    Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Morphological integrity of the outer retinal layers and visual prognosis in chronic central serous chorioretinopathy after half-dose photodynamic therapy: a qualitative SD-OCT analysis.
    Gobeka HH; Mentes J; Nalcaci S; Oztas Z; Cay Y
    Lasers Med Sci; 2022 Dec; 38(1):9. PubMed ID: 36539551
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-Term Efficacy and Safety of Photodynamic Therapy in Patients With Chronic Central Serous Chorioretinopathy.
    Park YJ; Kim YK; Park KH; Woo SJ
    Ophthalmic Surg Lasers Imaging Retina; 2019 Dec; 50(12):760-770. PubMed ID: 31877221
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
    Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F
    Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
    [TBL] [Abstract][Full Text] [Related]  

  • 51. COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY.
    Kim DY; Lee JY; Lee EK; Kim JY
    Retina; 2020 Jun; 40(6):1191-1199. PubMed ID: 30897068
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical predictive factors and imaging biomarkers of treatment response to half dose PDT in patients with chronic central serous chorioretinopathy.
    Mirshahi R; Naseripour M; Ghomashi A; Falavarjani KG
    Photodiagnosis Photodyn Ther; 2024 Aug; 48():104224. PubMed ID: 38801855
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence.
    Park W; Kim M; Kim RY; Park YH
    Graefes Arch Clin Exp Ophthalmol; 2019 Oct; 257(10):2155-2161. PubMed ID: 31367848
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization.
    Hu YC; Chen YL; Chen YC; Chen SN
    Sci Rep; 2021 Jun; 11(1):13286. PubMed ID: 34168238
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term outcomes of half-fluence photodynamic therapy and eplerenone in chronic central serous chorioretinopathy: A comparative study.
    Manayath G; Verghese S; Ranjan R; Agrawal H; Khanna A; Narendran V; Chhablani J
    Eur J Ophthalmol; 2021 Nov; 31(6):3110-3116. PubMed ID: 33508971
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy.
    Park DG; Jeong S; Noh D; Sagong M
    Br J Ophthalmol; 2021 Jun; 105(6):844-849. PubMed ID: 32727733
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative evaluation of damage to retinal capillaries caused by half-dose and half-time photodynamic therapy with optical coherent tomographic angiography.
    Xu F; Lai K; Zhou L; Huang C; Gong Y; Li L; Li C; Zhao H; Lu L; Jin C
    Photodiagnosis Photodyn Ther; 2021 Dec; 36():102477. PubMed ID: 34375777
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy.
    Senturk F; Karacorlu M; Ozdemir H; Karacorlu SA; Uysal O
    Am J Ophthalmol; 2011 Feb; 151(2):303-9.e1. PubMed ID: 21168824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.